Investigation of the molecular pathogenesis of cardiac amyloidosis using 18F-flutemetamol and 11C-PiB PET/CT and 99mTc-HMDP scintigraphy. - FMM, PiB, and HMDP accumulation in cardiac amyloidosis

开始日期2023-09-11

申办/合作机构

Kagawa University

EUCTR2022-000686-40-IT

/ Unknown status临床2期IIT

Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis - pulsar

开始日期2023-05-04

申办/合作机构

Fondazione Toscana Gabriele Monasterio

NCT05374564

/ Recruiting临床1期IIT

Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy

18F-Flutemetamol (Vizamyl) is a radioactive diagnostic agent indicated and FDA-approved for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline. This study is designed to evaluate a novel use for 18F-Flutemetamol in cardiac amyloidosis.

开始日期2022-08-16

申办/合作机构

Yale University

[+1]

100 项与氟[18F]美他酚相关的临床结果

登录后查看更多信息

100 项与氟[18F]美他酚相关的转化医学

登录后查看更多信息

100 项与氟[18F]美他酚相关的专利（医药）

登录后查看更多信息

149

项与氟[18F]美他酚相关的文献（医药）

2025-01-01·ANNALS OF NUCLEAR MEDICINE

Interrater agreement and variability in visual reading of [18F] flutemetamol PET images

Article

作者: Ito, Shinji ; Ishii, Kenji ; Ishii, Kazunari ; Notomi, Keiji ; Toyama, Hiroshi ; Takeda, Akinori ; Ito, Kengo ; Kato, Takashi ; Nakamura, Akinori ; Nihashi, Takashi ; Sakurai, Keita ; Inui, Yoshitaka ; Ono, Hokuto ; Arahata, Yutaka ; Takenaka, Akinori

Abstract:

Objective:

The purpose of this study was to validate the concordance of visual ratings of [18F] flutemetamol amyloid positron emission tomography (PET) images and to investigate the correlation between the agreement of each rater and the Centiloid (CL) scale.

Methods:

A total of 192 participants, clinically classified as cognitively normal (CN) (n = 59), mild cognitive impairment (MCI) (n = 65), Alzheimer’s disease (AD) (n = 55), or non-AD dementia (n = 13), participated in this study. Three experts conducted visual ratings of the amyloid PET images for all 192 patients, assigning a confidence level to each rating on a three-point scale (certain, probable, or neither). The positive or negative determination of amyloid PET results was made by majority vote. The CL value was calculated using the CapAIBL pipeline.

Results:

Overall, 101 images were determined to be positive, and 91 images were negative. Of the 101 positive images, the three raters were in complete agreement for 92 images and in disagreement for 9 images. Of the 91 negative images, the three raters were in complete agreement for 75 images and in disagreement for 16 images. Interrater reliability among the three experts was particularly high, with both Fleiss’ kappa and Conger’s kappa measuring 0.83 (0.76–0.89). The CL values of the unanimous positive group were significantly greater than those of the other groups, whereas the CL values of the unanimous negative group were significantly lower than those of the other groups. Images with rater disagreement had intermediate CLs. In cases with a high confidence level, the positive or negative visual ratings were in almost complete agreement. However, as confidence levels decreased, experts’ visual ratings became more variable. The lower the confidence level was, the greater the number of cases with disagreement in the visual ratings.

Conclusion:

Three experts independently rated 192 amyloid PET images, achieving a high level of interrater agreement. However, in patients with intermediate amyloid accumulation, visual ratings varied. Therefore, determining positive and negative decisions in these patients should be performed with caution.

2024-12-01·NUCLEAR MEDICINE COMMUNICATIONS

Visual assessments of 11C-Pittsburgh compound-B PET vs. 18F-flutemetamol PET across the age spectrum

Article

作者: Jack, Clifford R. ; Kemp, Bradley J. ; Zeydan, Burcu ; Lesnick, Timothy G. ; Johnson, Derek R. ; Min, Paul H. ; Lowe, Val J. ; Kantarci, Orhun H. ; Przybelski, Scott A. ; Kantarci, Kejal ; Schwarz, Christopher G. ; Senjem, Matthew L.

Objective:

Visual assessments of amyloid-β PET, used for Alzheimer’s disease (AD) diagnosis and treatment evaluation, require a careful approach when different PET ligands are utilized. Because the gray matter (GM) and white matter (WM) ligand bindings vary with age, the objective was to investigate the agreement between visual reads of 11C- and 18F-PET scans.

Methods:

Cognitively unimpaired (CU) younger adults (N = 30; 39.5 ± 6.0 years), CU older adults (N = 30; 68.6 ± 5.9 years), and adults with AD (N = 22; 67.0 ± 8.5 years) underwent brain MRI, 11C-Pittsburgh compound-B (PiB)-PET, and 18F-flutemetamol-PET. Amyloid-β deposition was assessed visually by two nuclear medicine specialists on 11C-PiB-PET and 18F-flutemetamol-PET, and quantitatively by PET centiloids.

Results:

Seventy-two 11C-PiB-PET and 18F-flutemetamol-PET visual reads were concordant. However, 1 18F-flutemetamol-PET and 9 11C-PiB-PET were discordant with quantitative values. In four additional cases, while 11C-PiB-PET and 18F-flutemetamol-PET visual reads were concordant, they were discordant with quantitative values. Disagreements in CU younger adults were only with 11C-PiB-PET visual reads. The remaining disagreements were with CU older adults.

Conclusion:

Age, GM/WM binding, amyloid-β load, and disease severity may affect visual assessments of PET ligands. Increase in WM binding with age causes a loss of contrast between GM and WM on 11C-PiB-PET, particularly in CU younger adults, leading to false positivity. In CU older adults, increased WM signal may bleed more into cortical regions, hiding subtle cortical uptake, especially with 18F-flutemetamol, whereas 11C-PiB can detect true regional positivity. Understanding these differences will improve patient care and treatment evaluation in clinic and clinical trials.

2024-09-01·CURRENT PROBLEMS IN CARDIOLOGY

Advancements and challenges in cardiac amyloidosis imaging: A comprehensive review of novel techniques and clinical applications

Review

作者: Jawa, Zabah ; Hovseth, Chad ; Albulushi, Arif ; Sallam, Mansour ; Al Hajri, Ruqaya ; Al-Mukhaini, Mohammed ; El Hadad, Mohamed Gamal

Cardiac amyloidosis, characterized by amyloid fibril deposition in the myocardium, leads to restrictive cardiomyopathy and heart failure. This review explores recent advancements in imaging techniques for diagnosing and managing cardiac amyloidosis, highlighting their clinical applications, strengths, and limitations. Echocardiography remains a primary, non-invasive imaging modality but lacks specificity. Cardiac MRI (CMR), with Late Gadolinium Enhancement (LGE) and T1 mapping, offers superior tissue characterization, though at higher costs and limited availability. Scintigraphy with Tc-99m-PYP reliably diagnoses transthyretin (TTR) amyloidosis but is less effective for light chain (AL) amyloidosis, necessitating complementary diagnostics. Amyloid-specific PET tracers, such as florbetapir and flutemetamol, provide precise imaging and quantitative assessment for both TTR and AL amyloidosis. Challenges include differentiating between TTR and AL amyloidosis, early disease detection, and standardizing imaging protocols. Future research should focus on developing novel tracers, integrating multimodality imaging, and leveraging AI to enhance diagnostic accuracy and personalized treatment. Advancements in imaging have improved cardiac amyloidosis management. A multimodal approach, incorporating echocardiography, CMR, scintigraphy, and PET tracers, offers comprehensive assessment. Continued innovation in tracers and AI applications promises further enhancements in diagnosis, early detection, and patient outcomes.

项与氟[18F]美他酚相关的新闻（医药）

2025-03-30

·SYNAPSE

GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan

GE HealthCare has completed its acquisition of Sumitomo Chemical’s 50% stake in Nihon Medi-Physics (NMP), giving it full ownership. As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, is positioned to enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease. CHICAGO--(BUSINESS WIRE)--Mar. 31, 2025-- GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As part of GE HealthCare, NMP can further build on its expertise in developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease. Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, who will also become President of NMP, said: “We are delighted to welcome Nihon Medi-Physics to GE HealthCare, increasing our existing footprint and offering in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country. Japan is on a path to becoming a leader in the $7 billion molecular imaging global market and a center of excellence for Asian markets. As part of GE HealthCare, NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring next-generation radiopharmaceuticals to the Japan market and beyond.” NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable molecular imaging across neurology, cardiology and oncology procedures. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. GE HealthCare acquired Amersham plc in 2004, and subsequently held a 50% stake in NMP. The Company expects this transaction to be neutral to Adjusted EPS in year one and accretive thereafter.

并购诊断试剂

2025-01-13

·思齐俱乐部

跨国药企加速角逐AD新药赛道，新年迎重大进展！

阿尔茨海默病(AD)是一种会导致记忆力和其他认知功能逐渐衰退的致命性疾病。该疾病以记忆力损失和认知能力下降为主要特征，逐渐干扰日常生活活动。阿尔茨海默症还涉及其他认知领域的损害，如语言能力、思维能力、决策能力和执行功能。据相关统计数据，全球有3200万人患有阿尔茨海默病痴呆，其中中国阿尔茨海默病患者近983万人，目前AD患者仍存在巨大的尚未被满足的治疗需求，庞大的市场空间正吸引跨国药企加速角逐AD新药赛道。 2025年刚开启不久，当地时间1月8日，强生宣布，其在研Tau单抗Posdinemab获美国FDA快速通道资格，用于治疗早期阿尔茨海默病(AD)患者。资料显示，Posdinemab是一种针对磷酸化tau蛋白的单克隆抗体(mAb)，主要用于治疗早期AD患者。目前，强生正在对早期AD患者进行2b期研究，研究内部发现的tau定向单株抗体Posdinemab。该药物在针对AD患者脑脊液中与疾病相关的磷酸化tau蛋白上显示出了潜力，并在记忆剥夺疾病的非临床模型中阻止tau蛋白聚集的发展和扩散。 Posdinemab通过靶向磷酸化tau蛋白，旨在减少其在脑脊液中的积累，从而减缓或阻止AD的进展。这种机制有助于改善患者的认知功能和减缓疾病进程‌。据了解，针对阿尔兹海默病，很早就有学者提出类淀粉蛋白假说，认为可能是β类淀粉蛋白(Aβ)在大脑堆积导致阿尔茨海默病。近些年，全球范围内获批上市的AD新药也均为Aβ单抗。例如，2024年1月，国家药监网站显示，日本卫材药业(Eisai)和美国渤健公司(Biogen)联合开发的阿尔茨海默病新药仑卡奈单抗(lecanemab-irmb)获批上市，用于轻度阿尔茨海默症(AD)和阿尔茨海默症(AD)引起的轻度认知障碍(MCI)疾病的改善治疗。这是迄今为止头一款在我国获批上市的抗Aβ抗体药物。 2024年12 月 18 日，礼来宣布多奈单抗注射液(Donanemab)获药监局批准上市，用于治疗成人因阿尔茨海默病引起的轻度认知功能障碍和阿尔茨海默病轻度痴呆(AD)。多奈单抗是礼来开发的靶向被称为N3pG的修饰化β-淀粉样蛋白(Aβ)抗体药物，已被美国FDA授予治疗阿尔兹海默(AD)的突破性疗法认定以及优先审评资格。2023年1月，CDE网站显示将多奈单抗注射液纳入突破性治疗品种。更早的2012年，礼来的Amyvid(Florbetapir F18)获得美国FDA批准上市。我国于2018年开展Amyvid仿制药临床研究，相关企业有安迪科、北京欣翮等。此外， FDA 针对淀粉样蛋白的 PET 诊断药物还有通用电气医疗集团 2013 年获批的 flutemetamol F18(Vizamyl)和 Piramal Imaging 2014 年获批的 florbetaben F18(NeuraCeq)。而除了β淀粉样蛋白外，微管结合蛋白(Tau 蛋白)也被认为是引起阿尔茨海默病病情发展的主要原因。目前也有大批药企在开发这类药物。其中，渤健有三款针对 Tau 蛋白药物正在开发，分别是其与百时美施贵宝(BMS)共同研发的针对 Tau 蛋白 N 端片段(eTau)的抗体药物BIIB092、与 Ionis Pharmaceuticals 合作共同研发的BIIB080，以及针对 Tau 的抗体药物BIIB076。这些研究均处于 I 期或 II 期临床试验阶段。来源：制药网商务合作 130 6172 3098 zakk.cui@siqibest.com 点击阅读原文了解更多

突破性疗法优先审批上市批准快速通道加速审批

2024-11-30

·SYNAPSE

GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan, from Sumitomo Chemical

CHALFONT ST GILES, England--([BUSINESS WIRE](https://www.businesswire.com/))--GE HealthCare (Nasdaq: GEHC) has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing from Sumitomo Chemical (TYO: 4005) the 50% stake it does not already own. As part of GE HealthCare, NMP can build on its expertise developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease. Sumitomo and GE HealthCare expect the agreement to close in early 2025, subject to regulatory approvals. NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable clinical images across neurology, cardiology and oncology procedures, such as its amyloid visualization radiotracer, VIZAMYL® Injection (Flutemetamol (18F) Injection), used in the Alzheimer’s pathway; DaTSCAN® Injection (Ioflupane (¹²³I) injection) used to evaluate patients with suspected Parkinson’s Disease or Dementia with Lewy Bodies; and MYOVIEW® (Technetium (99mTc) Tetrofosmin), used in SPECT myocardial perfusion imaging for the evaluation of known or suspected coronary artery disease. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. In addition to 13 manufacturing facilities, NMP also focuses on research and development, including nonclinical and clinical development of radiotracers and theranostics research. GE HealthCare has held its 50% stake in NMP since acquiring Amersham plc in 2004 and holds three positions on its Board of Directors. Kevin O’Neill, President & CEO of the Pharmaceutical Diagnostics (PDx) segment of GE HealthCare, said: “As the third largest pharmaceutical market in the world1, and amongst the leading countries by number of cyclotrons2, Japan is on a path to becoming a leader in the $7 billion molecular imaging global market and a center of excellence for Asian markets. NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring novel products to the Japan market and beyond. This will strengthen our precision care strategy in Asia and our existing footprint in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country.” Hiroshi Ueda, Executive Vise President, Sumitomo Chemical, said: “We are proud of our 50-year relationship with NMP and our partnership with GE HealthCare to ensure patients in Japan could benefit from access to molecular imaging. At a time of exciting developments in the industry, following its discussions with Sumitomo Chemical, we believe GE HealthCare is the best owner to enable NMP to continue its successful growth journey. I would like to recognize NMP’s leadership and talented team for their significant achievements to date and their commitment to patients.” As a leading global medical technology and pharmaceutical diagnostics innovator, GE HealthCare provides both molecular imaging equipment and proprietary radiotracers used across major patient care areas. The recent U.S. FDA approval of GE HealthCare’s first-of-its-kind PET radiopharmaceutical, Flyrcado™ (flurpiridaz F 18 injection), its in-licensing of Phase II FAPI assets and broadening theranostics offerings are all examples of the company’s commitment to novel diagnostics that are shaping the future of molecular imaging to drive improved patient outcomes. GE HealthCare’s PDx segment is a global leader in imaging agents used to support over 120 million patient procedures per year globally, equivalent to four patient procedures every second. The Company expects this transaction to be neutral to Adjusted EPS3,4 in year one and accretive thereafter. GE HealthCare was advised by Solomon Partners Securities, LLC. **Forward-Looking Statements** This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction, and GE HealthCare Technologies Inc.’s (the “Company’s”) performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation. **About GE HealthCare Technologies Inc.** GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits. Follow us on [LinkedIn](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fgehealthcare&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=LinkedIn&index=1&md5=8b71aacc0c8a28615a479f49839b2367), [X](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2FGEHealthCare&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=X&index=2&md5=5d3e010c5b6762aa437c9ed721a93fae), [Facebook](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FGEHealthCare%2F&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=Facebook&index=3&md5=afb7811bf3d186531a1f0195046c19a3), [Instagram](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fgehealthcare%2F&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=Instagram&index=4&md5=3e9a372d9f56b271b045aed2f9b1ed7e), and [Insights](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gehealthcare.com%2Finsights&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=Insights&index=5&md5=528c8409aca3aa77dc9faa2bd39a47a3) for the latest news, or visit our website [https://www.gehealthcare.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gehealthcare.com%2F&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=https%3A%2F%2Fwww.gehealthcare.com&index=6&md5=149ee377d64e90ca25044fcc3fff9335) for more information. 1 [https://www.trade.gov/country-commercial-guides/japan-pharmaceuticals](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.trade.gov%2Fcountry-commercial-guides%2Fjapan-pharmaceuticals&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=https%3A%2F%2Fwww.trade.gov%2Fcountry-commercial-guides%2Fjapan-pharmaceuticals&index=7&md5=469d2d595d8ea2691b2fbf21839f9df1), accessed on October 29, 2024 2 [https://nucleus.iaea.org/sites/accelerators/Pages/Cyclotron.aspx](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnucleus.iaea.org%2Fsites%2Faccelerators%2FPages%2FCyclotron.aspx&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=https%3A%2F%2Fnucleus.iaea.org%2Fsites%2Faccelerators%2FPages%2FCyclotron.aspx&index=8&md5=2bd260a4b0f14e662995bcc8256bab6e), accessed on October 29, 2024 3 See our latest [earnings release](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestor.gehealthcare.com%2Fnode%2F10446%2Fpdf&esheet=54159612&newsitemid=20241201060498&lan=en-US&anchor=earnings+release&index=9&md5=200cc703972627cdc567e9acdbf69787) dated October 30, 2024 for the definition of Adjusted EPS. 4 Non-GAAP financial measure

并购上市批准

100 项与氟[18F]美他酚相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	氟[18F]美他酚	V09AX04	DB09151

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
造影剂	日本	Nihon Medi-Physics Co., Ltd.	2017-09-27
阿尔茨海默症	美国	GE Healthcare, Inc.	2013-10-25

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑淀粉样血管病	临床3期	美国	GE Healthcare Holdings, Inc.	2009-12-01
正常压力脑积水	临床3期	美国	GE Healthcare Holdings, Inc.	2009-12-01
轻度认知障碍	临床3期	美国	GE Healthcare Holdings, Inc.	2009-12-01
认知障碍	临床1期	中国	天津恒瑞医药有限公司	2025-03-03
认知功能障碍	临床申请批准	中国	通用电气药业（上海）有限公司	2022-01-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02317783 (CTgov)	临床2期	认知功能障碍 \| 乳腺癌	15	Functional Magnetic Resonance Imaging (fMRI)+[18F]fluoro-2-deoxy-D-glucose (FDG)+[18F]Flutemetamol	獵觸醖艱構鏇遞衊繭醖 = 餘艱顧醖襯鏇鑰鏇簾築夢餘網築壓蓋簾鑰夢積 (醖衊艱繭選範鹽獵遞襯, 遞襯壓憲鹽廠餘構淵鬱 ~ 蓋鬱築選鹹蓋膚觸鑰醖) 更多	-	2024-11-20
Pubmed \| J Nucl Cardiol	N/A	老年性心脏淀粉样变性	17	18F-flutemetamol	築艱膚衊蓋顧淵構憲壓(鑰襯廠醖壓憲鹹顧鹽齋) = 網壓鹹齋衊鹹製衊鏇衊願獵襯鏇醖憲鏇窪積壓 (顧範齋範積鹹顧夢築觸 )	-	2022-04-01
MDS2019	N/A	帕金森病 amyloid-β deposits	-	18F-Flutemetamol	簾獵蓋網艱繭鬱壓範醖(遞襯遞壓鬱鹽餘醖糧糧) = 夢範築範鑰膚獵顧觸鑰壓膚獵獵鏇觸衊鹽蓋襯 (醖繭遞觸膚繭鬱範齋選 )	-	2019-09-22
				18F-Flutemetamol	簾獵蓋網艱繭鬱壓範醖(遞襯遞壓鬱鹽餘醖糧糧) = 積淵築齋顧獵鏇鑰繭選壓膚獵獵鏇觸衊鹽蓋襯 (醖繭遞觸膚繭鬱範齋選 )
EANM2019	N/A	老年性心脏淀粉样变性	22	F-18-Flutemetamol (Verified Cardiac Amyloidosis)	簾鬱繭遞醖築獵製築顧(構顧選淵夢顧齋憲淵積) = significantly different results in CA and no CA patients 壓鹽鬱鏇觸築構選網廠 (範膚壓繭襯鏇憲廠鑰願 )	-	2019-09-18
				F-18-Flutemetamol (No Cardiac Amyloidosis)
ECTRIMS2019	N/A	多发性硬化症	-	11C- and 18F- tracers (MS patients)	夢淵壓顧繭糧窪顧窪築(網淵鹹鹽積範衊窪構廠) = 餘積選艱鬱淵觸艱蓋鬱壓構鹽築艱夢醖觸廠觸 (繭構繭齋選網齋憲夢積, 0.19)	-	2019-09-10
				11C- and 18F- tracers (Healthy controls)	夢淵壓顧繭糧窪顧窪築(網淵鹹鹽積範衊窪構廠) = 鏇網鬱衊蓋夢鑰繭獵繭壓構鹽築艱夢醖觸廠觸 (繭構繭齋選網齋憲夢積, 0.21)
AIBL (EANM2018)	N/A	-	-	18F-Flutemetamol (Amyloid Positive Subjects)	鹹艱網鹽醖顧獵遞簾選(壓範窪鏇襯蓋餘鏇獵窪) = 淵獵積憲蓋糧繭鏇廠壓選積選艱廠夢繭艱選廠 (鑰膚窪簾艱窪衊鑰簾選 )	积极	2018-09-18
				18F-Flutemetamol (Amyloid Negative Subjects)	鹹艱網鹽醖顧獵遞簾選(壓範窪鏇襯蓋餘鏇獵窪) = 願構憲蓋製鬱壓餘壓獵選積選艱廠夢繭艱選廠 (鑰膚窪簾艱窪衊鑰簾選 )
NCT01202994 (CTgov)	临床2期	阿尔茨海默症	27	18F-Flutemetamol	醖獵繭積蓋獵繭網鬱範(鑰蓋製繭廠膚夢膚鏇醖) = 觸糧淵窪繭夢鏇淵齋憲鹽築窪餘壓餘製廠鬱鬱 (糧窪選鬱選襯壓艱餘網, 1.30) 更多	-	2018-01-11
AAIC2017	N/A	Aβ	264	FLUTEMETAMOL (Healthy controls)	膚憲築醖製觸淵窪衊夢(積衊淵鹽餘膚餘餘選夢) = 糧鑰鹹範醖觸繭鬱築鏇顧艱鹹構網餘範簾鬱顧 (鹽膚鹽鏇憲蓋艱淵願廠, CV 9.2)	-	2017-07-01
				FLUTEMETAMOL (Mild Cognitive Impairment)	膚憲築醖製觸淵窪衊夢(積衊淵鹽餘膚餘餘選夢) = 窪餘鑰艱膚範鏇窪網顧顧艱鹹構網餘範簾鬱顧 (鹽膚鹽鏇憲蓋艱淵願廠, CV 3.1)
AAIC2017	N/A	amyloid beta \| Aβ42 \| t-tau ... 更多	50	[18F]FLUTEMETAMOL (CSF testing)	範蓋鹽壓積獵襯顧選顧(遞夢蓋夢範壓襯鑰壓簾) = 壓鑰繭襯膚壓獵遞衊窪積鏇齋鬱淵窪夢簾壓鏇 (窪鑰蓋遞顧鏇憲蓋網製 ) 更多	-	2017-07-01
NCT02813070 (CTgov)	临床2期	阿尔茨海默症 \| 轻度认知障碍	70	[18F] Flutemetamol	遞願襯衊餘鹹淵積繭鹽 = 鹹顧鑰選獵遞鏇製餘製夢觸鹹獵繭願積範鑰夢 (窪廠製窪憲積網襯齋簾, 壓鏇網廠壓餘憲齋衊襯 ~ 範鬱製襯壓鏇醖衊鹹構) 更多	-	2017-06-05